Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2024.
Highlights:
- Recognized record total revenue of $15.1 million in the second quarter of 2024.
- Delivered gross margin of 60.1% in the second quarter of 2024, compared to a gross margin of 58.7% in the second quarter of 2023.
- AVISE® CTD trailing twelve-month average selling price (ASP) of $401, a 25.3% increase over the trailing twelve-month ASP in the second quarter of 2023.
- Net loss of $3.0 million in the second quarter of 2024, a 40.8% improvement over the second quarter of 2023.
- Adjusted EBITDA loss of $1.6 million for the second quarter of 2024, a 53.5% improvement over the second quarter of 2023.
- Cash and cash equivalents were $24.5 million as of June 30, 2024.
- https://www.biospace.com/exagen-inc-reports-strong-second-quarter-2024-results-raises-guidance-due-to-record-performance
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.